Quinti Isabella, Mitrevski Milica
Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.
Front Immunol. 2017 Jun 16;8:697. doi: 10.3389/fimmu.2017.00697. eCollection 2017.
Intravenous immunoglobulin administered at replacement dosages modulates innate and adaptive immune cells in primary antibody deficiencies (PAD) in a different manner to what observed when high dosages are used or when their effect is analyzed by experimental conditions. The effects seem to be beneficial on innate cells in that dendritic cells maturate, pro-inflammatory monocytes decrease, and neutrophil function is preserved. The effects are less clear on adaptive immune cells. IVIg induced a transient increase of Treg and a long-term increase of CD4 cells. More complex and less understood is the interplay of IVIg with defective B cells of PAD patients. The paucity of data underlies the need of more studies on patients with PAD before drawing conclusions on the mechanisms of action of IVIg based on investigations.
以替代剂量给予的静脉注射免疫球蛋白对原发性抗体缺陷（PAD）患者的固有免疫细胞和适应性免疫细胞的调节方式，与使用高剂量时或在实验条件下分析其效果时所观察到的情况不同。这些作用似乎对固有免疫细胞有益，因为树突状细胞成熟，促炎单核细胞减少，中性粒细胞功能得以保留。对适应性免疫细胞的影响则不太明确。静脉注射免疫球蛋白可诱导调节性T细胞短暂增加以及CD4细胞长期增加。静脉注射免疫球蛋白与PAD患者有缺陷的B细胞之间的相互作用更为复杂且了解较少。数据的匮乏使得在基于研究得出静脉注射免疫球蛋白作用机制的结论之前，需要对PAD患者进行更多研究。
